Suppr超能文献

实验性糖尿病对大鼠心肌肾上腺素能和胆碱能受体的影响。

Effects of experimental diabetes on adrenergic and cholinergic receptors of rat myocardium.

作者信息

Williams R S, Schaible T F, Scheuer J, Kennedy R

出版信息

Diabetes. 1983 Oct;32(10):881-6. doi: 10.2337/diab.32.10.881.

Abstract

To more fully characterize the alterations in myocardial adrenergic and cholinergic receptors induced by the diabetic state, we investigated the binding characteristics of (--) [3H] dihydroalprenolol to beta adrenergic receptors (bAR), [3H] prazosin to alpha adrenergic receptors (aAR), and [3H] quinuclidinyl-benzilate to muscarinic cholinergic receptors (MCR) in myocardial membranes derived from rats 8 wk after treatment with streptozotocin. We also studied an equal number of animals from three control groups: free-eating nondiabetics, pair-weighted nondiabetics, and streptozotocin-treated animals treated daily with insulin. Diabetic hearts demonstrated 27% fewer bAR (P less than 0.01) and 31% fewer aAR (P less than 0.01) than free-eating controls, without changes in MCR, and without changes in antagonist affinity, agonist affinity, or agonist slope factor (pseudo-Hill coefficient) for any class of receptors. Food restriction had no effect on receptor characteristics, and treatment of diabetic rats with insulin prevented any downregulation of cardiac bAR or aAR. The parallel decrease in both bAR and aAR suggests that streptozotocin-induced hypothyroidism is not the primary causative factor of bAR downregulation in this model, since hypothyroidism produces upregulation of aAR. Furthermore, the lack of change in cardiac MCR suggests that the adrenergic receptor alterations are not the result of nonspecific abnormalities of protein synthesis in the diabetic heart. Further studies are required to establish the physiologic significance of these receptor alterations, but these data support the hypothesis that altered adrenergic receptor properties may underlie, at least in part, the chronotropic and inotropic abnormalities of cardiac performance that are associated with the diabetic state.

摘要

为了更全面地描述糖尿病状态诱导的心肌肾上腺素能和胆碱能受体的变化,我们研究了用链脲佐菌素治疗8周后的大鼠心肌膜中(--)[3H]二氢阿普洛尔与β肾上腺素能受体(bAR)、[3H]哌唑嗪与α肾上腺素能受体(aAR)以及[3H]喹核醇基苯甲酸酯与毒蕈碱胆碱能受体(MCR)的结合特性。我们还研究了来自三个对照组的数量相等的动物:自由进食的非糖尿病动物、配对体重的非糖尿病动物以及每天接受胰岛素治疗的链脲佐菌素处理动物。与自由进食的对照组相比,糖尿病心脏的bAR减少了27%(P<0.01),aAR减少了31%(P<0.01),MCR没有变化,并且任何一类受体的拮抗剂亲和力、激动剂亲和力或激动剂斜率因子(伪希尔系数)均无变化。食物限制对受体特性没有影响,用胰岛素治疗糖尿病大鼠可防止心脏bAR或aAR的任何下调。bAR和aAR的平行减少表明,链脲佐菌素诱导的甲状腺功能减退不是该模型中bAR下调的主要致病因素,因为甲状腺功能减退会导致aAR上调。此外,心脏MCR缺乏变化表明,肾上腺素能受体改变不是糖尿病心脏蛋白质合成非特异性异常的结果。需要进一步研究来确定这些受体改变的生理意义,但这些数据支持这样的假设,即肾上腺素能受体特性改变可能至少部分地是与糖尿病状态相关的心脏变时性和变力性异常的基础。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验